Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Xagena Salute

The results of several new sub-analyses of the phase IIIb AVERT ( Assessing Very Early Rheumatoid arthritis Treatment ) trial that investigated the use of Abatacept ( Orencia ) plus Methotrexate ( MTX ...


Rheumatoid arthritis is associated with increased cardiovascular morbidity and mortality attributed to traditional cardiovascular risk factors and/or the chronic systemic inflammation. Researchers ...


Etanercept ( Enbrel ) has been widely applied in the treatment of ankylosing spondylitis ( AS ). Previous meta-analyses have focused on comparing the differences in clinical outcomes between Etanercep ...


A study has evaluated the efficacy and safety of Adalimumab ( Humira ) in patients with juvenile idiopathic arthritis ( JIA ). Baseline demographic and clinical characteristics and disease activity ...


A study has investigated whether use of Adalimumab ( Humira ) decreases the frequency of attacks of anterior uveitis in patients with ankylosing spondylitis. Consecutive patients with ankylosing sp ...


High body mass index ( BMI ) is associated with increased risk of osteoarthritis ( OA ) and reduced risk of fragility fracture. However, the relationship between fragility fracture and osteoarthritis ...


Positive results from a phase 3 trial of investigational drug Sarilumab in rheumatoid arthritis ( RA ) patients who were inadequate responders to Methotrexate ( MTX ) therapy were presented at the Eur ...


The aim of the study was to assess efficacy and safety of TNF-alpha antagonists ( anti-TNF ) in a cohort of patients with juvenile idiopathic arthritis ( JIA ) who began treatment under 4 years old an ...


The European Commission ( EC ) has granted a licence extension for Enbrel ( Etanercept ) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis ( nr-axSpA ). Non-ra ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


A new study presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) has shown a significantly increased risk of myocardial infarction in patients with Sjögren's syndrome ( S ...


Data presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) have demonstrated the possibility of using biomarkers ( developed from whole blood gene expression profiles ) in ...


Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi ...


Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus Methotrexate or Methotrexate alone are unclear. ...


Two-year results from the ORAL Start study were published in The New England Journal of Medicine ( NEJM ). ORAL Start is a 24-month phase 3 study in patients with moderately to severely active rheumat ...